7T Amygdala and Citalopram Study

Sponsor
University of Oxford
Study ID
NCT06412315
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 40 Years
Healthy Volunteers
Accepted

Interventions

  • Citalopram — DRUG
    Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
  • Placebo — DRUG
    Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once

Study Details

The goal of this study is to investigate how a common antidepressant citalopram (which increases the levels of the chemical messenger serotonin), affects how a key area of the brain involved in depression (the amygdala) responds to emotional information. Healthy participants will undergo medical and psychiatric health screening, after which they will be assigned to receive either a single dose of citalopram (20mg) or placebo, and undergo brain scanning (7T fMRI) whilst viewing emotional faces. Since the scan uses high field strength, the investigators will be able to see effects of citalopram on different subfields within the amygdala which will help to understand how citalopram might be working.

Key Dates

First listed
May 14, 2024
Start date
Feb 13, 2025
Status verified
Feb 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Citalopram
  • Placebo Comparator: Placebo

Primary Outcome Measure

Neural measures: fMRI BOLD univariate analysis [ Time Frame: 3 hours after dosing for approximately 1 hour ]

Central Contacts

Find similar trials

Nationwide
Depression trialsPsychiatry trialsMental health trialsBehavioral health trials

Related Studies